The influence of renal function by ibuprofen treatment for patent ductus arteriosus in extremely low-birth-weight infants.
Recently, ibuprofen (IBU) has been used for the treatment of patent ductus arteriosus (PDA) in Japan. We aimed to investigate the efficacy and adverse events of IBU and compared them with those of indomethacin (IND) as PDA treatment for extremely low-birth-weight infants (ELBWIs), focusing on short-term renal function. A case-control study was conducted on 16 ELBWIs. The data from eligible patients were divided into two groups. Ten patients had undergone IND treatment (IND group) between January 2017 and June 2018, whereas six had undergone IBU treatment (IBU group) for PDA between July 2018 and December 2018. The IND group received 0.1 mg/kg/12 h IND IV infusion for three doses, whereas the IBU group received 10 mg/kg IV IBU infusion followed by 5 mg/kg/day for 2 days. We compared the efficacy for PDA closure and renal impairment between the two groups. No significant differences in primary closure rates and required PDA ligation were observed between the two groups. No significant differences were observed between the incidence of IVH and gastrointestinal complications in both groups. Changes in urine volume (%) in the IBU group was significantly higher than that in the IND group at 24-36 h post-administration. The urinary L-FABP concentration level at 7 days of life was significantly lower in the IBU group than those in the IND group. These results the advantages of investigating PDA treatment with IBU in preventing short-term renal function rather than IND in ELBWIs.